BioScrip Reports Third Quarter 2018 Financial Results
06 Novembre 2018 - 2:00PM
BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the
largest independent national provider of infusion and home care
management solutions, today announced its third quarter 2018
financial results.
Third Quarter 2018
Highlights
- Net revenue of $181.0 million, compared to $198.7 million in
the third quarter of 2017. Excluding exited UHC therapy line
revenue from the prior year quarter, net revenue increased
approximately 5%.
- Net loss from continuing operations of $8.1 million, a $5.0
million improvement compared to the prior year quarter.
- Adjusted EBITDA of $16.4 million, 25% above the prior year
quarter, driven by a 510 basis point improvement in gross profit
margin, reflecting ASC 606 pro forma adjustments.
- Core mix increased to 75.7%, a 60 basis point sequential
increase compared to the second quarter of 2018, and a 10 basis
point increase compared to the prior year quarter.
- Net cash provided by operating activities of $0.2 million in
the third quarter, reflecting operational cash flow of $13.8
million, offset by interest payments of $13.6 million, including
bi-annual bond interest payments of $8.8 million.
- Liquidity of $18.9 million at September 30, 2018, consisting of
cash and cash equivalents.
Daniel E. Greenleaf, President and Chief
Executive Officer, commented, “BioScrip achieved record third
quarter adjusted EBITDA driven by revenue growth, higher gross
profit margin, and ongoing operating expense discipline. We
delivered comparable revenue growth for the first time since the
fourth quarter of 2015. Given the team’s strong third quarter
performance and our momentum that is expected to continue into the
fourth quarter, we are increasing full year 2018 guidance for
revenue between $710 million and $720 million*, and maintaining our
adjusted EBITDA guidance between $54 million and $58 million.”
“Further, we remain increasingly confident that
BioScrip can achieve at least $75 million in adjusted EBITDA in
2019, as the Company is positioned for continued revenue growth in
line with market growth rates, and enhanced profitability though
key initiatives in revenue cycle management, procurement and
managed care relationships.”
* Implementation of ASC 606 during the first
quarter of 2018 resulted in the recognition of amounts previously
recorded as bad debt expense as a reduction to revenue. The impact
of the change in accounting principle reduced both revenue and bad
debt expense by $5.7 million during the third quarter. The
implementation of ASC 606 did not impact operating income or
Adjusted EBITDA during the third quarter of 2018 and will not
impact operating income or Adjusted EBITDA on a go-forward
basis.
Conference Call and
Presentation
BioScrip will host a conference call and live
webcast on November 6, 2018, at 9:00 a.m. Eastern Time, to discuss
its third quarter 2018 financial results. Interested parties
may participate by dialing 877-423-9820 (U.S.) or by accessing a
link under the "Investors" section on the Company's website at
www.bioscrip.com.
An audio webcast and archive will be available
within two hours of the call’s completion under the “Investors"
section of the Company's website.
About BioScrip, Inc.
BioScrip, Inc. is the largest independent
national provider of infusion and home care management solutions,
with approximately 2,100 teammates and nearly 70 service locations
across the U.S. BioScrip partners with physicians, hospital
systems, payors, pharmaceutical manufacturers and skilled nursing
facilities to provide patients access to post-acute care services.
BioScrip operates with a commitment to bring customer-focused
pharmacy and related healthcare infusion therapy services into the
home or alternate-site setting. By collaborating with the full
spectrum of healthcare professionals and the patient, BioScrip
provides cost-effective care that is driven by clinical excellence,
customer service, and values that promote positive outcomes and an
enhanced quality of life for those it serves.
Investor
Contacts |
|
Stephen Deitsch |
Kalle Ahl, CFA |
Chief Financial Officer
& Treasurer |
The Equity Group |
T: (720)
697-5200 |
T: (212)
836-9614 |
stephen.deitsch@bioscrip.com |
kahl@equityny.com |
Forward-Looking Statements – Safe Harbor
This press release includes statements that may
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including the
statements regarding guidance, projections of certain measures of
the Company's results of operations, projections of future levels
of certain charges and expenses, incremental cost structure
improvements and other statements regarding the Company's financial
improvement plan and strategy and anticipated effects of the Cures
Act. You can identify these statements by the fact that they do not
relate strictly to historical or current facts. In some cases,
forward-looking statements can be identified by words such as
"may," "should," "could," "anticipate," "estimate," "expect,"
"project," "outlook," "aim," "intend," "plan," "believe,"
"predict," "potential," "continue" or comparable terms. Because
such statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or
implied by such forward-looking statements. Investors are cautioned
that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, and that
actual results may differ materially from those in the
forward-looking statements as a result of various factors.
Important factors that could cause actual results to differ
materially from those in the forward-looking statement include but
are not limited to risks associated with: the Company’s ability to
make principal and interest payments on our debt and unsecured
notes and satisfy the other covenants contained in its debt
agreements; the Company’s ability to grow its core Infusion
revenues; the Company's ability to continue to execute its
financial improvement plan to reduce operating costs and focus its
business on its Infusion Services segment; the Company’s ability to
evaluate opportunities for improvement and implement solutions as
part of its strategic review process; the success of the Company’s
initiatives to mitigate the impact of the Cures Act on its
business; reductions in federal, state and commercial reimbursement
for the Company's products and services; increased government
regulation related to the health care and insurance industries; as
well as the risks described in the Company's periodic filings with
the Securities and Exchange Commission. The Company does not
undertake any duty to update these forward-looking statements after
the date hereof, even though the Company's situation may change in
the future. All of the forward-looking statements herein are
qualified by these cautionary statements.
Note Regarding Use of Non-GAAP Financial
Measures
In addition to reporting financial information
in accordance with generally accepted accounting principles (GAAP),
the Company is also reporting Adjusted EBITDA, which is a non-GAAP
financial measure. Adjusted EBITDA is not a measurement of
financial performance under GAAP and should not be used in
isolation or as a substitute or alternative to net income,
operating income or any other performance measure derived in
accordance with GAAP, or as a substitute or alternative to cash
flow from operating activities or a measure of the Company’s
liquidity. In addition, the Company's definition of Adjusted EBITDA
may not be comparable to similarly titled non-GAAP financial
measures reported by other companies. Adjusted EBITDA, as defined
by the Company, represents net income before net interest expense,
income tax expense, depreciation and amortization, impairment of
goodwill, stock-based compensation expense, and restructuring,
integration and other expenses. As part of restructuring, the
Company may incur significant charges such as the write down of
certain long−lived assets, temporary redundant expenses, retraining
expenses, potential cash bonus payments and potential accelerated
payments or terminated costs for certain of its contractual
obligations. Management believes that Adjusted EBITDA provides
useful supplemental information regarding the performance of
BioScrip’s business operations and facilitates comparisons to the
Company’s historical operating results. For a full reconciliation
of Adjusted EBITDA to the most comparable GAAP financial measure,
please see the attachment to this earnings release.
Schedule 1 |
BIOSCRIP, INC. AND SUBSIDIARIES |
CONSOLIDATED BALANCE SHEETS |
(in thousands, except for share amounts) |
(unaudited) |
|
|
|
|
|
September 30, 2018 |
|
December 31, 2017 |
|
|
|
|
ASSETS |
|
|
|
Current
assets |
|
|
|
Cash and cash
equivalents |
$ |
18,944 |
|
|
$ |
39,457 |
|
Restricted cash |
|
4,320 |
|
|
|
4,950 |
|
Accounts
receivable, net of allowance for doubtful accounts of $0 and
$37,912 as of |
|
|
|
September
30, 2018 and December 31, 2017, respectively |
|
113,628 |
|
|
|
85,522 |
|
Inventory |
|
23,105 |
|
|
|
38,044 |
|
Prepaid
expenses and other current assets |
|
11,944 |
|
|
|
18,620 |
|
Total current assets |
|
171,941 |
|
|
|
186,593 |
|
Property and equipment,
net of accumulated depreciation of $97,788 and $88,298 as of |
|
|
|
September
30, 2018 and December 31, 2017, respectively |
|
25,177 |
|
|
|
26,973 |
|
Goodwill |
|
367,198 |
|
|
|
367,198 |
|
Intangible assets, net
of accumulated amortization of $47,120 and $40,436 as of September
30, 2018 |
|
|
|
and
December 31, 2017, respectively |
|
12,030 |
|
|
|
19,114 |
|
Deferred taxes |
|
990 |
|
|
|
1,098 |
|
Other non-current
assets |
|
1,836 |
|
|
|
2,116 |
|
Total assets |
$ |
579,172 |
|
|
$ |
603,092 |
|
LIABILITIES AND
STOCKHOLDERS' DEFICIT |
|
|
|
Current
liabilities |
|
|
|
Current
portion of long-term debt |
$ |
2,076 |
|
|
$ |
1,722 |
|
Accounts
payable |
|
63,901 |
|
|
|
65,963 |
|
Amounts
due to plan sponsors |
|
1,546 |
|
|
|
4,621 |
|
Accrued
interest |
|
2,268 |
|
|
|
6,706 |
|
Accrued
expenses and other current liabilities |
|
26,204 |
|
|
|
26,118 |
|
Total current liabilities |
|
95,995 |
|
|
|
105,130 |
|
Long-term debt, net of
current portion |
|
496,770 |
|
|
|
478,866 |
|
Other non-current
liabilities |
|
22,744 |
|
|
|
21,769 |
|
Total liabilities |
|
615,509 |
|
|
|
605,765 |
|
Series A
convertible preferred stock, $.0001 par value; 825,000 shares
authorized; |
|
|
|
21,630
and 21,645 shares issued and outstanding as of September 30, 2018
and |
|
|
|
December
31, 2017, respectively; and $3,172 and $2,916 liquidation
preference as of |
|
|
|
September
30, 2018 and December 31, 2017, respectively |
|
3,126 |
|
|
|
2,827 |
|
Series C
convertible preferred stock, $.0001 par value; 625,000 shares
authorized; |
|
|
|
614,177
shares issued and outstanding as of September 30, 2018 and December
31, 2017; |
|
|
|
and
$92,038 and $84,555 liquidation preference as of September 30, 2018
and |
|
|
|
December 31, 2017, respectively |
|
87,225 |
|
|
|
79,252 |
|
Stockholders'
deficit |
|
|
|
Preferred stock, $.0001 par value; 5,000,000 shares
authorized; no shares issued and |
|
|
|
outstanding as of September 30, 2018 and December 31, 2017,
respectively |
|
- |
|
|
|
- |
|
Common stock, $.0001 par value; 250,000,000 shares authorized;
128,064,145 and 127,634,012 |
|
|
shares
issued and outstanding as of September 30, 2018 and December 31,
2017, respectively |
|
13 |
|
|
|
13 |
|
Treasury stock, 287,248 and 5,106 shares outstanding, at cost,
as of September 30, 2018 and |
|
|
December
31, 2017, respectively |
|
(849 |
) |
|
|
(16 |
) |
Additional paid-in capital |
|
619,989 |
|
|
|
624,762 |
|
Accumulated deficit |
|
(745,841 |
) |
|
|
(709,511 |
) |
Total stockholders' deficit |
|
(126,688 |
) |
|
|
(84,752 |
) |
Total liabilities and stockholders' deficit |
$ |
579,172 |
|
|
$ |
603,092 |
|
Schedule 2 |
BIOSCRIP, INC. AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF
OPERATIONS |
(in thousands, except per share amounts) |
(unaudited) |
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
|
|
2018 |
|
|
|
2017 |
|
|
|
2018 |
|
|
|
2017 |
|
|
|
|
|
|
|
|
|
Net revenue |
$ |
180,962 |
|
|
$ |
198,692 |
|
|
$ |
525,335 |
|
|
$ |
634,608 |
|
Cost of revenue (excluding depreciation
expense) |
|
115,051 |
|
|
|
132,129 |
|
|
|
344,419 |
|
|
|
435,560 |
|
Gross profit |
|
65,911 |
|
|
|
66,563 |
|
|
|
180,916 |
|
|
|
199,048 |
|
% of
revenues |
|
36.4 |
% |
|
|
33.5 |
% |
|
|
34.4 |
% |
|
|
31.4 |
% |
|
|
|
|
|
|
|
|
Other operating expenses |
|
38,216 |
|
|
|
38,143 |
|
|
|
116,378 |
|
|
|
124,755 |
|
Bad debt expense |
|
- |
|
|
|
6,488 |
|
|
|
- |
|
|
|
19,648 |
|
General and administrative expenses |
|
12,478 |
|
|
|
9,405 |
|
|
|
34,084 |
|
|
|
28,325 |
|
Restructuring, acquisition, integration, and other expenses |
|
885 |
|
|
|
4,037 |
|
|
|
4,789 |
|
|
|
11,407 |
|
Change in fair value of equity linked liabilities |
|
1,605 |
|
|
|
1,103 |
|
|
|
1,228 |
|
|
|
1,103 |
|
Depreciation and amortization expense |
|
5,767 |
|
|
|
7,058 |
|
|
|
18,617 |
|
|
|
21,288 |
|
Interest expense |
|
14,971 |
|
|
|
13,360 |
|
|
|
42,171 |
|
|
|
38,649 |
|
Loss on extinguishment of debt |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
13,453 |
|
Loss (gain) on dispositions |
|
(10 |
) |
|
|
(33 |
) |
|
|
(330 |
) |
|
|
652 |
|
Loss from continuing operations, before
income taxes |
|
(8,001 |
) |
|
|
(12,998 |
) |
|
|
(36,021 |
) |
|
|
(60,232 |
) |
Income tax expense |
|
102 |
|
|
|
60 |
|
|
|
191 |
|
|
|
1,397 |
|
Loss from continuing operations, net of
income taxes |
|
(8,103 |
) |
|
|
(13,058 |
) |
|
|
(36,212 |
) |
|
|
(61,629 |
) |
Income (loss) from discontinued operations, net of income
taxes |
|
(71 |
) |
|
|
66 |
|
|
|
(118 |
) |
|
|
(606 |
) |
Net loss |
$ |
(8,174 |
) |
|
$ |
(12,992 |
) |
|
$ |
(36,330 |
) |
|
$ |
(62,235 |
) |
Accrued dividends on
preferred stock |
|
(2,861 |
) |
|
|
(2,569 |
) |
|
|
(8,272 |
) |
|
|
(7,435 |
) |
Loss attributable to common
stockholders |
$ |
(11,035 |
) |
|
$ |
(15,561 |
) |
|
$ |
(44,602 |
) |
|
$ |
(69,670 |
) |
|
|
|
|
|
|
|
|
Loss per common share: |
|
|
|
|
|
|
|
Loss from continuing operations, basic and diluted |
$ |
(0.09 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.35 |
) |
|
$ |
(0.56 |
) |
Loss from discontinued operations, basic and diluted |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(0.01 |
) |
Loss per common share, basic and diluted |
$ |
(0.09 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.35 |
) |
|
$ |
(0.57 |
) |
|
|
|
|
|
|
|
|
Weighted average number of common shares
outstanding, |
|
|
|
|
|
|
|
basic and diluted |
|
127,528 |
|
|
|
127,488 |
|
|
|
127,893 |
|
|
|
122,519 |
|
Schedule 3 |
BIOSCRIP, INC. AND SUBSIDIARIES |
QUARTERLY
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES |
(in thousands) |
(unaudited) |
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
|
|
2018 |
|
|
|
2017 |
|
|
|
2018 |
|
|
|
2017 |
|
|
|
|
|
|
|
|
|
Loss from continuing operations, net of income
taxes |
$ |
(8,103 |
) |
|
$ |
(13,058 |
) |
|
$ |
(36,212 |
) |
|
$ |
(61,629 |
) |
|
|
|
|
|
|
|
|
Interest expense |
|
(14,971 |
) |
|
|
(13,360 |
) |
|
|
(42,171 |
) |
|
|
(38,649 |
) |
Change in fair value of equity linked liabilities |
|
(1,605 |
) |
|
|
(1,103 |
) |
|
|
(1,228 |
) |
|
|
(1,103 |
) |
Gain (loss) on dispositions |
|
10 |
|
|
|
33 |
|
|
|
330 |
|
|
|
(652 |
) |
Loss on extinguishment of debt |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(13,453 |
) |
Income tax expense |
|
(102 |
) |
|
|
(60 |
) |
|
|
(191 |
) |
|
|
(1,397 |
) |
Depreciation and amortization expense |
|
(5,767 |
) |
|
|
(7,058 |
) |
|
|
(18,617 |
) |
|
|
(21,288 |
) |
Stock-based compensation expense |
|
(1,224 |
) |
|
|
(545 |
) |
|
|
(3,032 |
) |
|
|
(1,525 |
) |
Restructuring, acquisition, integration, and other expenses
(1) |
|
(885 |
) |
|
|
(4,037 |
) |
|
|
(4,789 |
) |
|
|
(11,407 |
) |
Consolidated Adjusted EBITDA |
$ |
16,441 |
|
|
$ |
13,072 |
|
|
$ |
33,486 |
|
|
$ |
27,845 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Restructuring, acquisition,
integration and other expenses include costs associated with
restructuring, acquisition, and integration initiatives such as
employee severance costs, certain legal and professional fees,
redundant wage costs, impacts recorded from the change in
contingent consideration obligations, and other costs related to
contract terminations and closed locations. |
|
|
|
|
|
|
|
|
Schedule 4 |
BIOSCRIP, INC AND SUBSIDIARIES |
CONSOLIDATED CONDENSED CASH
FLOWS |
(in thousands) |
(unaudited) |
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
March 31,
2018 |
|
June 30,
2018 |
|
September 30,
2018 |
|
September 30,
2018 |
Cash flows from operating activities: |
|
|
|
|
|
|
|
Net loss |
$ |
(13,017 |
) |
|
$ |
(15,139 |
) |
|
$ |
(8,174 |
) |
|
$ |
(36,330 |
) |
Less: Loss from discontinued operations, net of income taxes |
|
(30 |
) |
|
|
(15 |
) |
|
|
(73 |
) |
|
|
(118 |
) |
Loss from continuing operations, net of income taxes |
|
(12,987 |
) |
|
|
(15,124 |
) |
|
|
(8,101 |
) |
|
|
(36,212 |
) |
Adjustments to reconcile net loss from continuing operations, net
of income taxes to net cash used in operating activities: |
|
|
|
|
|
|
|
Depreciation and amortization |
|
6,486 |
|
|
|
6,366 |
|
|
|
5,765 |
|
|
|
18,617 |
|
Amortization of deferred financing costs and debt
discount |
|
2,023 |
|
|
|
2,048 |
|
|
|
2,013 |
|
|
|
6,084 |
|
Change in fair value of equity linked
liabilities |
|
(3,439 |
) |
|
|
3,064 |
|
|
|
1,603 |
|
|
|
1,228 |
|
Change in deferred income taxes |
|
31 |
|
|
|
25 |
|
|
|
52 |
|
|
|
108 |
|
Stock-based compensation |
|
556 |
|
|
|
1,253 |
|
|
|
1,223 |
|
|
|
3,032 |
|
Paid-in-kind interest capitalized as principal on
Second Lien Note Facility |
|
- |
|
|
|
- |
|
|
|
3,800 |
|
|
|
3,800 |
|
Gain on dispositions |
|
(305 |
) |
|
|
(13 |
) |
|
|
(12 |
) |
|
|
(330 |
) |
Changes in assets and liabilities: |
|
|
|
|
|
|
|
Accounts receivable |
|
(2,663 |
) |
|
|
(8,734 |
) |
|
|
(16,709 |
) |
|
|
(28,106 |
) |
Inventory |
|
(3,505 |
) |
|
|
16,264 |
|
|
|
2,180 |
|
|
|
14,939 |
|
Prepaid expenses and other assets |
|
8,807 |
|
|
|
1,247 |
|
|
|
(3,098 |
) |
|
|
6,956 |
|
Accounts payable |
|
2,872 |
|
|
|
(19,574 |
) |
|
|
14,640 |
|
|
|
(2,062 |
) |
Amounts due to plan sponsors |
|
(969 |
) |
|
|
(1,468 |
) |
|
|
(638 |
) |
|
|
(3,075 |
) |
Accrued interest |
|
(4,487 |
) |
|
|
4,510 |
|
|
|
(4,461 |
) |
|
|
(4,438 |
) |
Accrued expenses and other liabilities |
|
2,418 |
|
|
|
(4,984 |
) |
|
|
1,899 |
|
|
|
(667 |
) |
Net cash used in operating activities from
continuing operations |
|
(5,162 |
) |
|
|
(15,120 |
) |
|
|
156 |
|
|
|
(20,126 |
) |
Net cash used in operating activities from
discontinued operations |
|
(30 |
) |
|
|
(15 |
) |
|
|
(72 |
) |
|
|
(117 |
) |
Net cash provided by (used in) operating
activities |
|
(5,192 |
) |
|
|
(15,135 |
) |
|
|
84 |
|
|
|
(20,243 |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
|
Purchases of property and equipment |
|
(2,646 |
) |
|
|
(4,300 |
) |
|
|
(2,462 |
) |
|
|
(9,408 |
) |
Net cash used in investing
activities |
|
(2,646 |
) |
|
|
(4,300 |
) |
|
|
(2,462 |
) |
|
|
(9,408 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
|
Borrowing of long-term debt |
|
- |
|
|
|
10,000 |
|
|
|
- |
|
|
|
10,000 |
|
Repayments of capital leases |
|
(967 |
) |
|
|
(218 |
) |
|
|
(438 |
) |
|
|
(1,623 |
) |
Net activity from exercises of employee stock
awards |
|
(300 |
) |
|
|
121 |
|
|
|
310 |
|
|
|
131 |
|
Net cash provided by (used in) financing
activities |
|
(1,267 |
) |
|
|
9,903 |
|
|
|
(128 |
) |
|
|
8,508 |
|
Net change in cash, cash equivalents and restricted cash |
|
(9,105 |
) |
|
|
(9,532 |
) |
|
|
(2,506 |
) |
|
|
(21,143 |
) |
Cash, cash equivalents and restricted cash - beginning of
period |
|
44,407 |
|
|
|
35,302 |
|
|
|
25,770 |
|
|
|
44,407 |
|
Cash, cash equivalents and restricted cash - end of
period |
$ |
35,302 |
|
|
$ |
25,770 |
|
|
$ |
23,264 |
|
|
$ |
23,264 |
|
Schedule
5 |
|
|
|
|
BIOSCRIP, INC AND SUBSIDIARIES |
FULL YEAR 2018
GUIDANCE |
(dollars in millions, except EPS) |
|
Low
End |
|
High
End |
|
of
Range |
|
of
Range |
|
|
|
|
Revenues |
$ |
710.0 |
|
|
$ |
720.0 |
|
|
|
|
|
Loss from continuing operations, net of income
taxes |
|
(41.4 |
) |
|
|
(33.9 |
) |
|
|
|
|
Interest
expense |
|
58.0 |
|
|
|
57.0 |
|
Change in fair
value of equity linked liabilities |
|
1.2 |
|
|
|
1.2 |
|
Gain on
dispositions |
|
(0.3 |
) |
|
|
(0.3 |
) |
Income tax
expense |
|
0.8 |
|
|
|
0.3 |
|
Depreciation and
amortization |
|
25.0 |
|
|
|
24.0 |
|
Stock-based
compensation |
|
4.7 |
|
|
|
4.2 |
|
Restructuring,
acquisition, integration, and other expenses |
|
6.0 |
|
|
|
5.5 |
|
Consolidated Adjusted EBITDA |
$ |
54.0 |
|
|
$ |
58.0 |
|
Consolidated Adjusted EBITDA
Margin |
|
7.6 |
% |
|
|
8.1 |
% |
|
|
|
|
Diluted Loss Per Common
Share |
$ |
(0.32 |
) |
|
$ |
(0.26 |
) |
Weighted-Average
Diluted Shares |
|
128.0 |
|
|
|
128.0 |
|
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024